Drug Profile

NECVAX NEO1

Alternative Names: NECVAX-NEO1

Latest Information Update: 27 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NEC Corporation; VAXIMM
Developer NEC OncoImmunity
Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Solid tumours; Triple negative breast cancer

Most Recent Events

24 Oct 2026 Phase-I/II clinical trials in Triple-negative-breast-cancer (First-line therapy, Neoadjuvant therapy) in USA (PO) (NCT06631092)
24 Oct 2026 US FDA approves IND application for NECVAX NEO1 in Triple Negative Breast Cancer, prior to October 2026
24 Oct 2026 Efficacy and adverse events data from a phase I/II trial in triple negative breast cancer released by NEC Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com